#Drug discovery #epilepsy #Gene therapy

EpilepsyGTx partners with ClearPoint for gene therapy delivery  

Biotechnology company EpilepsyGTx has partnered with ClearPoint Neuro on a project that will support the targeted delivery of the biotech’s gene therapy candidate, EPY201, for focal refractory epilepsy (FRE).  The agreement will see EpilepsyGTx use the ClearPoint SmartFlow Cannula and the ClearPoint Neuro Navigation system to administer EPY201 in its upcoming first-in-human Phase I/IIa clinical trial for FRE.  ClearPoint’s MRI-guided stereotactic… Read More

20 July 2026 #News

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford

DDW Highlights: 7 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More

7 July 2026 #Podcasts

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

3 July 2026 #News

#epilepsy #Gene therapy #Protein

New gene therapy could prevent epilepsy, study suggests 

A new type of gene therapy that only activates when the brain is under stress could stop epilepsy before it fully develops, researchers say.  In a study led by Professor Tawfeeq Shekh-Ahmed of the School of Pharmacy at the Hebrew University of Jerusalem (HU), published in Signal… Read More

1 July 2026 #News

#epilepsy #Neurology #University College London

EpilepsyGTx appoints Co-Founder Dimitri Kullman as CSO 

Biotechnology company EpilepsyGTx has appointed Professor Dimitri Kullman as Chief Scientific Officer.  As a Co-Founder of EpilepsyGTx, the company says Kullmann’s role as CSO will shape and execute scientific strategy, setting research priorities and overseeing the delivery of its pipeline programmes.  EpilepsyGTx sees Kullmann as an internationally recognised leader in… Read More

1 May 2026 #News

#Cell therapy #epilepsy #Mergers and acquisitions #Neurona Therapeutics #Neuroscience #UCB

UCB to acquire epilepsy specialists Neurona Therapeutics

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio.   Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.  UCB will pay $650 million upfront and up… Read More

24 April 2026 #Business & Investment #News

#Brain #epilepsy #Novel therapeutics

Angelini and Quiver to collaborate on epilepsy therapeutics 

Brain health company Angelini Pharma has announced a strategic collaboration with biotechnology company Quiver Bioscience to discover and advance novel therapeutics to genetic epilepsies.  The collaboration, which also includes a licensing agreement, brings together Quiver’s drug discovery capabilities, data assets and AI models with Angelini Pharma’s expertise in brain health and… Read More

25 February 2026 #News

#CDMO #epilepsy #Neurology

Neumirna and ten23 partner to advance epilepsy treatments

Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases.  The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring… Read More

30 October 2025 #News

#epilepsy #Longboard Pharmaceuticals #Lundbeck #Mergers and acquisitions #Neurology

Acquisition to strengthen neuroscience pipeline

Lundbeck and Longboard Pharmaceuticals have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation superagonist mechanism specifically targeting… Read More

15 October 2024 #Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

29 July 2024 #News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

26 July 2024 #News

#Africa #Collaboration #epilepsy #LMICs #University of Oxford

Oxford centre to address global epilepsy challenges

The University of Oxford is launching The Centre for Global Epilepsy to address the global burden of epilepsy, particularly in lower-income countries. Based at Wolfson College, Oxford, the Centre for Global Epilepsy will collaborate with key research institutions and epilepsy clinics worldwide, linking expertise from high-income… Read More

23 July 2024 #News

#AI / data analytics / healthtech / informatics #epilepsy #Interview #Omics #Sitting Down With

Sitting down with… Stefanie Dedeurwaerdere, UCB

Stefanie Dedeurwaerdere is Global Strategy Lead for Pipeline Development in Global Epilepsy & Rare Syndromes at UCB. In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical treatment pipeline to… Read More

5 March 2024 #Exclusive Content #Opinion

#epilepsy #Gene therapy #Mouse models #Preclinical investigations #University College London

Gene therapy could reduce seizures in childhood epilepsy

University College London (UCL) researchers have developed a new gene therapy to cure focal cortical dysplasia, which a new study shows can significantly reduce seizures in mice. Focal cortical dysplasia is caused by areas of the brain that have developed abnormally and is among the most… Read More

18 December 2023 #Editor's Choice #News

#Alzheimer's #epilepsy #Neuroinflammation #Parkinson's #Phase I trial #Ventus Therapeutics

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Based on the safety margins demonstrated in IND-enabling studies, the Phase I trial is designed to fully explore VENT-02’s pharmacodynamics, safety, and… Read More

24 August 2023 #News

#Biotherapeutics #Bloom Science #epilepsy #Phase I trial

Live biotherapeutic could treat rare paediatric epilepsy

Bloom Science has completed enrolment of healthy adult participants as part of its Phase I clinical trial into BL-001 for Dravet syndrome, a rare paediatric epilepsy. BL-001 is an orally administered Live Biotherapeutic Product reverse translated from the positive clinical outcomes associated with the Ketogenic Diet… Read More

1 May 2023 #News